GlobeNewswire by notified

Constellation Brands Announces New Leadership Appointments

Share

VICTOR, N.Y., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, today announced a number of new leadership appointments designed to position the company for sustained and industry-leading performance over the long term.

“One of the hallmarks of our company’s success over many years has been our relentless focus on continuing to find ways to position Constellation Brands for sustained and industry-leading performance,” said Bill Newlands, Constellation Brands’ President and Chief Executive Officer. “Continuing to invest in our talent to further strengthen leadership capabilities, broaden skill sets and perspective, and to enhance overall business acumen and strategic orientation is foundational to achieving our future ambitions.”

The aforementioned new leadership appointments are as follows:

Beer Division

Mallika Monteiro has assumed expanded responsibility for beer marketing while continuing to lead the company’s innovation, consumer insights, and digital functions as EVP, Chief Growth & Digital Officer and Managing Director, Beer Brands. Monteiro brings prior experience in beer and brand marketing and a deep understanding of consumer trends, preferences, and motivations to this role. Since joining Constellation in 2016, she has held a number of leadership roles with increasing responsibility, helping to accelerate Constellation’s innovation capabilities and driving portfolio growth through consumer-focused insights.

Matt Lindsay has been appointed SVP, Chief Marketing Officer– Beer Division. In this new role, Lindsay is responsible for leading the company’s beer marketing functions including Brand Marketing; Field, Lifestyle & Experiential Marketing; Trade Marketing; and Marketing Enablement. He joined Constellation in 2022 as SVP, Brand Marketing.

Greg Gallagher has been appointed SVP, Brand Marketing, assuming responsibility for all brand marketing efforts related to Constellation’s beer portfolio. Formerly as VP, Brand Marketing – Modelo, Gallagher’s contributions were integral in delivering award winning marketing strategies for the Modelo brand family, helping Modelo Especial secure its #1 selling position in dollar sales in U.S. tracked channels.

Rene Ramos has been appointed SVP, Brand Activation with responsibility for Field, Lifestyle & Experiential Marketing, as well as Trade Marketing. Ramos joined Constellation in 2013 and has played a key role in helping drive consumer connections through integrated and compelling brand experiences and sponsorships.

John Kester has been appointed SVP, Chief Supply Chain Officer – Beer, responsible for leading the company’s integrated end-to-end supply chain organization. Kester joined Constellation in 2014 and has played a key role in enhancing the company’s sourcing, procurement, transportation and logistics functions. He brings 30 years of beer industry experience across all facets of supply chain operations, across multiple geographies.

Innovation, Consumer Insights & Digital

Andrew Zrike has been appointed SVP, Innovation & Consumer Insights for the company’s beer and wine and spirits businesses. In this new role, Zrike leads a team responsible for developing integrated brand growth plans and ensuring consumer preferences and trends remain at the center of the company’s brand building efforts. Zrike joined Constellation in 2019 and has helped lead the development of a number of consumer-driven innovations including Modelo Oro, Modelo Aguas Frescas, and Corona Non-Alcoholic.

Karena Breslin has assumed expanded responsibilities as SVP, Digital, Transformation & Media, leading the company’s transformation and digital business acceleration efforts, in addition to her continued oversight of Constellation’s digital, media and marketing technology functions. Breslin joined Constellation in 2010 and has held a number of leadership roles with increased responsibility over time, establishing Constellation’s digital marketing function and accelerating the company’s eCommerce capabilities.

Corporate Strategy

Mike McGrew has assumed expanded responsibilities for corporate strategy and analytics, in addition to leading the company’s communications, ESG and diversity efforts as EVP, Chief Communications, Strategy, ESG & Diversity Officer. McGrew joined Constellation in 2014 and has held a number of progressive leadership roles, helping to evolve and enhance the company’s strategies and capabilities in areas including communications and public relations, investor relations, corporate social responsibility, and diversity, equity, and inclusion.

Finance

Michael Becka has assumed expanded responsibilities as SVP, Corporate Finance, where he will serve as lead for the company’s Tax, Controller, and Treasury teams. Becka joined Constellation in 2017 and has been instrumental in managing the company’s tax strategies.

Sandy Dominach has assumed expanded responsibilities as SVP, Beer Finance, in addition to overseeing the company’s Enterprise Risk Management function. Dominach has held a number of Finance leadership roles in Treasury, Financial Planning, and Enterprise Risk Management since joining Constellation in 2003.

Joe Suarez has been appointed SVP, Investor Relations. Suarez joined Constellation in 2021 and has focused on evolving the company’s investor engagement strategy and reinforcing Constellation’s reputation as a differentiated and high-growth investment opportunity.

Steve King has been appointed SVP, Corporate Development, and Financial Planning & Analytics. King has served in a number of roles with increasing responsibility in areas such as audit, financial analysis, financial management, and business development since joining Constellation in 2008.

“While we’ve had tremendous success over the years, I believe we’re only scratching the surface and the best is yet to come,” said Newlands. “These new leadership appointments will help equip our rising leaders with the perspective and capabilities needed to keep our company on the forefront of emerging consumer and marketplace trends, and they exemplify the deep bench strength of talent we have across the organization to continue driving our business forward.”

ABOUT CONSTELLATION BRANDS
Constellation Brands (NYSE: STZ) is a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Our mission is to build brands that people love because we believe elevating human connections is Worth Reaching For. It’s worth our dedication, hard work, and calculated risks to anticipate market trends and deliver more for our consumers, shareholders, employees, and industry. This dedication is what has driven us to become one of the fastest-growing, large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what’s next.

Every day, people reach for our high-end, iconic imported beer brands such as those in the Corona brand family like the flagship Corona Extra, Modelo Especial and the flavorful lineup of Modelo Cheladas, Pacifico, and Victoria; our fine wine and craft spirits brands including The Prisoner Wine Company, Robert Mondavi Winery, Casa Noble Tequila, and High West Whiskey; and our premium wine brands such as Kim Crawford and Meiomi.

As an agriculture-based company, we have a long history of operating sustainably and responsibly. Our ESG strategy is embedded into our business and our work focuses on serving as good stewards of the environment, enhancing social equity within our industry and communities, and promoting responsible beverage alcohol consumption. These commitments ground our aspirations beyond driving the bottom line as we work to create a future that is truly Worth Reaching For.

To learn more, visit www.cbrands.com and follow us on XInstagram, and LinkedIn.

FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements. The words “expect” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements may relate to business strategy, future operations, prospects, plans and objectives of management, as well as information concerning expected actions of third parties, including statements related to Constellation’s investment in talent and future ambitions or performance. All forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those set forth in, or implied by, such forward-looking statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur.

The forward-looking statements are based on management’s current expectations and should not be construed in any manner as a guarantee that such actions will in fact occur or will occur on the timetable contemplated hereby. All forward-looking statements speak only as of the date of this news release and Constellation undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

In addition to risks and uncertainties associated with ordinary business operations, the forward-looking statements contained in this news release are subject to other risks and uncertainties, including those disclosed from time-to-time in Constellation’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended February 28, 2023 and its Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2023, which could cause actual future performance to differ from current expectations.

MEDIA CONTACTSINVESTOR RELATIONS CONTACTS
Amy Martin 585-678-7141 / amy.martin@cbrands.com
Carissa Guzski 315-525-7362 / carissa.guzski@cbrands.com

Joseph Suarez 773-551-4397 / joseph.suarez@cbrands.com
Snehal Shah 847-385-4940 / snehal.shah@cbrands.com
David Paccapaniccia 585-282-7227 / david.paccapaniccia@cbrands.com

A downloadable PDF copy of this news release can be found here: http://ml.globenewswire.com/Resource/Download/10e85351-7319-4781-b7bc-45b5c2c78de9

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria24.2.2024 15:51:43 CET | Press release

Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed rilzabrutinib, an oral BTK inhibitor, significantly reduced weekly itch severity score (ISS7) as early as the first week of treatment in adults with moderate to severe CSUData form the basis for the Phase 3 CSU and prurigo nodularis programs to start in 2024Pivotal Phase 3 readout in immune thrombocytopenia and Phase 2 readouts in asthma, IgG4-related disease and warm autoimmune hemolytic anemia expected in 2024Rilzabrutinib is one of 12 potential blockbusters in Sanofi’s leading immunology pipeline Paris, February 24, 2024. Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines. These r

Application to delist from Nasdaq First North Growth Market Denmark submitted24.2.2024 14:17:57 CET | Press release

Copenhagen, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Announcement no. 3-2024 Hypefactors has submitted an official application to delist from Nasdaq First North Growth Market Denmark. A decision backed by 98,42% of the share capital represented at the Extraordinary General Meeting held on 23. February 2024 Delisting requires the final approval from Nasdaq. The details of​ the delisting ​procedure and ​consequenses for shareholders is stated in the company announcement 01-2024. ---- About Hypefactors A/S Hypefactors is an AI based reputation and corporate trust technology company, providing a tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work, and all the facts to document the results. In addition to media monitoring across the different media channels, the platform provides access to several facts, incl. a

798 Launches Folk Culture Sector of Square Art Festival, 110,000+ Visitors Reached During the Chinese New Year Vacation24.2.2024 03:00:00 CET | Press release

BEIJING, Feb. 24, 2024 (GLOBE NEWSWIRE) -- 798 Art District announces today that the Folk Culture Sector of the 798 Square Art Festival will launch on February 24, 2024, at the CONCERTED SQUARE of 798 Art District in Beijing. This sector aims to bridge contemporary art with urban and rural folk culture. Visiting 798 during the Lantern Festival, you can experience the power of contemporary art intertwined with traditional folk customs and enjoy the familiar yet strange world of Chinese local culture. Event Poster February 24 is the Lantern Festival in China, and it marks the end of the Chinese New Year festivities. The New Year vacation in 798 was full of lively atmosphere. Throughout the Spring Festival, 15 exhibitions were ongoing in 798, including the Joy Art Museum's "Joy in the Year of the Dragon", IOMA Art Center's "Dragon Roaming the World and Prospering", MOCUBE's "Upon Arrival of Dragon", and Le Rime Gallery's "Jia Chen Mountain Chronicle". Based on statistics, there were over

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®24.2.2024 02:15:00 CET | Press release

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchan

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons23.2.2024 23:50:47 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameJan G. J. van de Winkel2.Reason for the notificationa)Position/statusPresident & Chief Executive Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform,

HiddenA line styled icon from Orion Icon Library.Eye